Alcohol Cravings & Alcohol Use Disorder

Alcohol use disorder (AUD) is a medical condition marked by an impaired ability to stop or control drinking despite harm to health, work or relationships. It covers what people call alcohol abuse, alcohol dependence, alcohol addiction and alcoholism. Clinicians grade it with DSM-5 criteria: mild (2–3 criteria), moderate (4–5) or severe (6 or more). An estimated 28 million Americans aged 12 and older had AUD in 2024. Only 7.6% of them received any alcohol treatment that year, and just 2.5% received medication for it. Worldwide, AUD accounts for about 5% of deaths each year.

Interest in peptides for drinking took off as patients and clinicians reported that people on GLP-1 drugs for diabetes or weight loss were drinking less. In one analysis of Reddit posts about these drugs, 71% of the alcohol-related posts described reduced craving or less desire to drink. Animal research in mice, rats and non-human primates had pointed the same way. Since 2022, randomized trials of exenatide, dulaglutide, injectable semaglutide, oral semaglutide and the GLP-1/glucagon agonist pemvidutide have tested it in people. The results are mixed but increasingly positive. As of October 2026, no GLP-1-class peptide is FDA-approved for AUD. Three medications are approved for it, and they remain first line: naltrexone, acamprosate and disulfiram.

This page covers the trial evidence, the remaining gaps, and how these drugs might fit alongside proven care. One rule matters most. Someone who has been drinking heavily for a long time can develop dangerous, even fatal, withdrawal if they stop suddenly. No peptide treats withdrawal or replaces medically supervised detox. If you need help now, SAMHSA's National Helpline at 1-800-662-HELP (4357) is free, confidential and open 24/7. This page is informational, not medical advice.

How peptides target alcohol cravings & alcohol use disorder

GLP-1 is best known as a gut hormone that boosts insulin and curbs appetite, but GLP-1 receptor agonists also act on the brain's reward system. In animal studies, they reduce alcohol intake, the motivation to drink and relapse-like drinking. They also blunt alcohol's rewarding effects, including dopamine release in the nucleus accumbens. In the exenatide AUD trial, brain imaging showed weaker responses to alcohol cues in the ventral striatum and septal area, regions central to reward and addiction. The leading hypothesis is that these drugs reduce the reward people get from alcohol and so reduce drinking. Reviewers note that slower stomach emptying, nausea and stress responses may also contribute.

Newer multi-receptor peptides extend the idea. Tirzepatide adds GIP receptor agonism. A 2026 rodent study found it reduced alcohol reward, voluntary drinking, binge drinking and relapse-like drinking. Eli Lilly is developing brenipatide, a once-monthly GIP/GLP-1 agonist, with AUD as a lead indication. Pemvidutide pairs GLP-1 with glucagon receptor agonism. It is being developed mainly for fatty liver disease (MASH), and Altimmune is also testing it in alcohol-associated liver disease.

The clinical appeal is clear. The approved AUD medications have modest effects, and only about 2.5% of people with AUD received medication for it in 2024. GLP-1 drugs already treat obesity and type 2 diabetes, which some people with AUD also have. A drug that reduces drinking and improves metabolic health would fill a real gap. Mechanistic plausibility and patient anecdotes are not proof, though, and the controlled trials are more nuanced than the headlines.

What the evidence shows

Semaglutide has the most human evidence, from three randomized trials. In the first (Hendershot et al., JAMA Psychiatry 2025), 48 adults with AUD who were not seeking treatment took low-dose semaglutide (0.25 mg then 0.5 mg weekly, with a final week at 1.0 mg) or placebo for 9 weeks. Semaglutide reduced how much people drank in a laboratory drinking session, along with drinks per drinking day and weekly craving. It did not reduce the number of drinking days or average drinks per day. The larger SEMALCO trial (Klausen et al., Lancet 2026) enrolled 108 treatment-seeking adults with moderate-to-severe AUD and obesity. Participants took semaglutide 2.4 mg weekly or placebo for 26 weeks, on top of cognitive behavioral therapy. Heavy drinking days fell 41.1 percentage points from baseline on semaglutide and 26.4 on placebo, a 13.7-point difference (p=0.0015). An oral semaglutide trial (Schacht et al., Am J Psychiatry 2026; n=50, 8 weeks) missed its primary endpoint of laboratory cue-induced craving and did not reduce drinks per day. It did reduce heavy drinking days, drinks per drinking day, everyday craving and alcohol-related consequences.

The older GLP-1 drugs give mixed results. Exenatide had the first dedicated AUD trial (Klausen et al., 2022; n=127, 26 weeks, plus therapy), and it missed its primary endpoint of fewer heavy drinking days. Exploratory analyses found reduced heavy drinking and total intake in participants with a BMI above 30. The same Danish group then ran SEMALCO specifically in people with AUD and obesity (BMI 30 or higher). Dulaglutide data come from a prespecified secondary analysis of a smoking-cessation trial (Probst et al., 2023). Among 151 drinkers, dulaglutide users drank 29% less than placebo users at 12 weeks. Liraglutide has no AUD trial. In a Swedish nationwide cohort of 227,866 people with AUD (Lähteenvuo et al., 2025), periods on semaglutide were associated with a 36% lower risk of AUD hospitalization and periods on liraglutide with a 28% lower risk. The approved AUD medications showed only a 2% lower risk in the same analysis. Observational designs cannot prove cause and effect, and the cohort captured mainly people prescribed these drugs for obesity or diabetes.

Newer peptides are earlier in development. Pemvidutide's Phase 2 RECLAIM trial (about 100 adults with AUD and BMI above 25, 24 weeks) reported in July 2026 that heavy drinking days per week fell by 4.20 on pemvidutide and 2.75 on placebo (p=0.0014). Two-level drops in WHO drinking-risk level occurred in 64.4% versus 34.8%. Those results are company-reported topline data and not yet peer-reviewed. Tirzepatide's human evidence so far is self-reported and observational, including a 2023 study combining Reddit post analysis with a remote survey. Several Phase 2 tirzepatide AUD trials are recruiting. Brenipatide is in two Phase 3 AUD trials of about 1,100 participants each (NCT07219953 and NCT07219966), with primary completion expected in 2028. The VA's Phase 3 CRAVE trial of semaglutide in 622 veterans with AUD (NCT07218354) began in July 2026. Lilly's Phase 2 mazdutide AUD trial completed in May 2026, but results have not been released.

The approved medications give useful context. A 2023 JAMA meta-analysis of 118 trials found that 11 people need to take oral naltrexone (50 mg/day) to prevent one return to heavy drinking, and 11 need to take acamprosate to prevent one return to any drinking. GLP-1 trials have not yet shown whether they match, beat or add to these drugs. The current evidence is consistent with real but moderate effects on heavy drinking, strongest in people with obesity, with Phase 3 confirmation still pending.

What to expect

In the trials, doses were raised step by step over weeks, and outcomes were measured over 8 to 26 weeks. The typical pattern was drinking less per occasion and fewer heavy drinking days, rather than quitting outright. In the first semaglutide trial, drinks per drinking day fell but the number of drinking days did not change. Trial results are averages, and individual responses vary.

The placebo group in SEMALCO also improved substantially, cutting heavy drinking days by 26 percentage points. Every participant in that trial received cognitive behavioral therapy, which is a reminder that counseling and structure do much of the work. The most common side effects listed on the Ozempic label are nausea, vomiting, diarrhea, abdominal pain and constipation. No trial has shown how long any benefit lasts after the drug is stopped.

The strongest results so far come from people with overweight or obesity. No trial has run longer than 26 weeks, so long-term outcomes are unknown. A GLP-1 drug is not a detox, a cure, or a reason to skip therapy, mutual-support groups or approved medications.

Frequently asked questions

References

• Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical TrialRandomized Controlled Trial

  Hendershot CS et al., JAMA Psychiatry 2025. Phase 2 trial of 48 adults with AUD who were not seeking treatment, 9 weeks of low-dose semaglutide. Semaglutide reduced laboratory alcohol self-administration, drinks per drinking day and weekly craving, but not drinking days or average drinks per day. This was the first randomized trial of semaglutide in AUD.

• Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trialRandomized Controlled Trial

  Klausen MK et al., Lancet 2026 (SEMALCO). 108 treatment-seeking adults with moderate-to-severe AUD and obesity took semaglutide 2.4 mg weekly or placebo for 26 weeks, plus cognitive behavioral therapy. Heavy drinking days fell 13.7 percentage points more with semaglutide (p=0.0015).

• Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical TrialRandomized Controlled Trial
• Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trialRandomized Controlled Trial
• Effects of dulaglutide on alcohol consumption during smoking cessationRandomized Controlled Trial
• Repurposing Semaglutide and Liraglutide for Alcohol Use DisorderCohort Study
• Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-AnalysisMeta-Analysis

  McPheeters M et al., JAMA 2023. 118 trials, 20,976 participants. Together with psychosocial treatment, the evidence supports oral naltrexone (50 mg/day) and acamprosate as first-line AUD medications. This is the benchmark any GLP-1-based AUD therapy will be measured against.

• Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use DisorderPress Release

Part of these goals

Related conditions

• NAFLD & MASLD
• Depression
• Anxiety
• Insomnia

Stacks that overlap

• CagriSema / CagriTriz / CagriReta (Cagrilintide + GLP-1 Agonist)

  A family of weekly injectable obesity stacks that pair the long-acting amylin analog cagrilintide with a GLP-1 receptor agonist — semaglutide (CagriSema), tirzepatide (CagriTriz), or retatrutide (CagriReta). Only CagriSema has completed pivotal clinical trials; the other two are conceptual compounded or investigational combinations.